PMID- 36586476
OWN - NLM
STAT- MEDLINE
DCOM- 20230314
LR  - 20230322
IS  - 1878-1780 (Electronic)
IS  - 1262-3636 (Linking)
VI  - 49
IP  - 2
DP  - 2023 Mar
TI  - Association between metabolic dysfunction-associated fatty liver disease and 
      supraventricular and ventricular tachyarrhythmias in patients with type 2 
      diabetes.
PG  - 101416
LID - S1262-3636(22)00097-0 [pii]
LID - 10.1016/j.diabet.2022.101416 [doi]
AB  - BACKGROUND: Currently, it remains uncertain whether metabolic 
      dysfunction-associated fatty liver disease (MAFLD) is associated with increased 
      risk of supraventricular and ventricular tachyarrhythmias in people with type 2 
      diabetes mellitus (T2DM). METHODS: We retrospectively examined the data of 367 
      ambulatory patients with T2DM who underwent 24-hour Holter monitoring between 
      2015 and 2022 for clinical indications, and who did not have pre-existing 
      permanent atrial fibrillation (AF), kidney failure or known liver diseases. 
      Paroxysmal supraventricular tachycardia (PSVT), paroxysmal AF and episodes of 
      ventricular tachyarrhythmias (i.e., presence of ventricular tachycardia, >30 
      premature ventricular complexes per hour, or both) were recorded. The presence 
      and severity of MAFLD was diagnosed by ultrasonography and fibrosis-4 (FIB-4) 
      index. RESULTS: Patients with T2DM who had MAFLD (n = 238) had a significantly 
      greater prevalence of PSVT (51.7% vs. 38.8%), paroxysmal AF (6.3% vs. 1.3%) and 
      combined ventricular tachyarrhythmias (31.9% vs. 20.2%) compared to their 
      counterparts without MAFLD (n = 129). MAFLD was significantly associated with a 
      greater than two-fold risk of having PSVT (adjusted-odds ratio [OR] 2.04, 95% 
      confidence interval 1.04-4.00) or ventricular tachyarrhythmias (adjusted-OR 2.44, 
      95%CI 1.16-5.11), after adjusting for age, sex, smoking, alcohol intake, 
      diabetes-related factors, comorbidities, medication use and left ventricular 
      ejection fraction on echocardiography. The risk of supraventricular and 
      ventricular tachyarrhythmias was even greater amongst patients with MAFLD and 
      FIB-4 >/= 1.3. CONCLUSIONS: In ambulatory patients with T2DM, the presence and 
      severity of MAFLD was strongly associated with an increased risk of 
      supraventricular and ventricular arrhythmias on 24-hour Holter monitoring.
CI  - Copyright (c) 2022 Elsevier Masson SAS. All rights reserved.
FAU - Mantovani, Alessandro
AU  - Mantovani A
AD  - Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, 
      University of Verona, Verona, Italy.
FAU - Csermely, Alessandro
AU  - Csermely A
AD  - Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, 
      University of Verona, Verona, Italy.
FAU - Taverna, Antonio
AU  - Taverna A
AD  - Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, 
      University of Verona, Verona, Italy.
FAU - Cappelli, Davide
AU  - Cappelli D
AD  - Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, 
      University of Verona, Verona, Italy.
FAU - Benfari, Giovanni
AU  - Benfari G
AD  - Section of Cardiology, Department of Medicine, University of Verona, Verona, 
      Italy.
FAU - Bonapace, Stefano
AU  - Bonapace S
AD  - Division of Cardiology, ''Sacro Cuore'' Hospital, Negrar (VR), Italy.
FAU - Byrne, Christopher D
AU  - Byrne CD
AD  - Nutrition and Metabolism, Faculty of Medicine, University of Southampton, UK; 
      Southampton National Institute for Health Research Biomedical Research Centre, 
      University Hospital Southampton, Southampton General Hospital, Tremona Road, 
      Southampton, UK.
FAU - Targher, Giovanni
AU  - Targher G
AD  - Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, 
      University of Verona, Verona, Italy. Electronic address: 
      giovanni.targher@univr.it.
LA  - eng
PT  - Journal Article
DEP - 20221228
PL  - France
TA  - Diabetes Metab
JT  - Diabetes & metabolism
JID - 9607599
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/complications
MH  - Stroke Volume
MH  - Retrospective Studies
MH  - Ventricular Function, Left
MH  - *Non-alcoholic Fatty Liver Disease/complications
MH  - *Tachycardia, Ventricular/complications/diagnosis
MH  - *Atrial Fibrillation/epidemiology
OTO - NOTNLM
OT  - Arrhythmias
OT  - Cardiovascular disease
OT  - MAFLD
OT  - Metabolic dysfunction-associated fatty liver disease
OT  - NAFLD
OT  - Nonalcoholic fatty liver disease
OT  - Type 2 diabetes
COIS- Declaration of Competing Interest All authors declare no conflicts of interest.
EDAT- 2023/01/01 06:00
MHDA- 2023/03/15 06:00
CRDT- 2022/12/31 19:13
PHST- 2022/11/19 00:00 [received]
PHST- 2022/12/21 00:00 [revised]
PHST- 2022/12/23 00:00 [accepted]
PHST- 2023/01/01 06:00 [pubmed]
PHST- 2023/03/15 06:00 [medline]
PHST- 2022/12/31 19:13 [entrez]
AID - S1262-3636(22)00097-0 [pii]
AID - 10.1016/j.diabet.2022.101416 [doi]
PST - ppublish
SO  - Diabetes Metab. 2023 Mar;49(2):101416. doi: 10.1016/j.diabet.2022.101416. Epub 
      2022 Dec 28.